Akoya Biosciences appoints Dr. Myla Lai-Goldman to its Board of Directors

– USA, CA –  Akoya Biosciences, Inc. (NASDAQ: AKYA), The Spatial Biology Company, today announced the appointment of Dr. Myla Lai-Goldman (MD) a true pioneer and leader in the diagnostic industry, to its board of directors.

“We are excited and honored to have Myla join the board of Akoya as the company embarks on a new phase of growth,” said CEO, Brian McKelligon. “Myla is an established leader and visionary in the life sciences and diagnostics markets. Her experience leading organizations in all phases of diagnostic testing, from discovery to development and commercialization, will help Akoya achieve its ultimate goal of improving patients’ lives.”

About Dr. Myla Lai-Goldman

Dr. Lai-Goldman has extensive experience in all aspects of the diagnostics industry. From 1990 to 2008, Dr. Lai-Goldman held various roles including EVP, CMO, and CSO at Laboratory Corporation of America Holdings (LabCorp) and its predecessor company, Roche Biomedical Laboratories, Inc. During her tenure at LabCorp, she led all clinical, scientific, and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. Dr. Lai‐Goldman is currently the Chair of GeneCentric Therapeutics, a precision medicine company, which she co-founded and previously served as CEO and President. She is also a venture partner with Hatteras Venture Partners and managing partner of Personalized Science, LLC, a diagnostic consulting company that she founded in 2008. Board-certified in both anatomic and clinical pathology, she received her medical degree from Columbia University College of Physicians and Surgeons.

“It is an honor to join the board of Akoya, a company that is providing innovative spatial biology solutions with the potential to transform the life sciences market,” said Dr. Lai-Goldman. “Akoya’s platforms provide an unprecedented capability to understand the relationship of cells to their tumor microenvironment and span applications from discovery and clinical research. The groundbreaking discoveries emanating from this work could dramatically increase our understanding of patient response to therapy and ultimately improve the standard of care.”

About Akoya Biosciences

As The Spatial Biology Company, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.

For more information: https://www.akoyabio.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team